



Universiteit
Leiden

The Netherlands

Multi-modality imaging in ischemic heart disease, arrhythmia and cardiac-mechanics

El Mahdiui, M.

Citation

El Mahdiui, M. (2022, May 10). *Multi-modality imaging in ischemic heart disease, arrhythmia and cardiac-mechanics*. Retrieved from <https://hdl.handle.net/1887/3303502>

Version: Publisher's Version


License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3303502>

Note: To cite this publication please use the final published version (if applicable).

PART I

**Imaging modalities in coronary
artery disease**



Sex Differences in Coronary Plaque Changes assessed by Serial Computed Tomography Angiography

El Mahdiui M, Smit JM, van Rosendael AR, Neglia D, Knuuti J, Saraste A, Buechel RR, Teresinska A, Pizzi MN, Roque A, Magnacca M, Mertens BJ, Caselli C, Rocchiccioli S, Parodi O, Pelosi G, Scholte AJ.

Int J Cardiovasc Imaging. 2021 Mar 10.

ABSTRACT

Long-term data on sex-differences in coronary plaque changes over time is lacking in a low-to-intermediate risk population of stable coronary artery disease (CAD). The aim of this study was to evaluate the role of sex on long-term plaque progression and evolution of plaque composition. Furthermore, the influence of menopause on plaque progression and composition was also evaluated. Patients that underwent a coronary computed tomography angiography (CTA) were prospectively included to undergo a follow-up coronary CTA. Total and compositional plaque volumes were normalized using the vessel volume to calculate a percentage atheroma volume (PAV). To investigate the influence of menopause on plaque progression, patients were divided into two groups, under and over 55 years of age. In total, 211 patients were included in this analysis, 146 (69%) men. The mean interscan period between baseline and follow-up coronary CTA was 6.2 ± 1.4 years. Women were older, had higher HDL levels and presented more often with atypical chest pain. Men had 434 plaque sites and women 156. On a per-lesion analysis, women had less fibro-fatty PAV compared to men ($\beta -1.3 \pm 0.4\%$; $p < 0.001$), with no other significant differences. When stratifying patients by 55 years age threshold, fibro-fatty PAV remained higher in men in both age groups ($p < 0.05$) whilst women younger than 55 years demonstrated more regression of fibrous ($\beta -0.8 \pm 0.3\%$ per year; $p = 0.002$) and non-calcified PAV ($\beta -0.7 \pm 0.3\%$ per year; $p = 0.027$). In a low-to-intermediate risk population of stable CAD patients, no significant sex differences in total PAV increase over time were observed. Fibro-fatty PAV was lower in women at any age and women under 55 years demonstrated significantly greater reduction in fibrous and non-calcified PAV over time compared to age-matched men. (ClinicalTrials.gov number, NCT04448691.)

INTRODUCTION

Several studies have highlighted distinct sex-related differences for coronary artery disease (CAD). Women tend to be older when presenting with CAD¹, have lower rates of obstructive disease² but higher risk of major adverse cardiac events compared to men²⁻⁵. This discrepancy might arise from differences in plaque characteristics between men and women.⁶ Postmortem histology studies reported plaque morphological differences between men and women⁷⁻¹⁰. However, in vivo intravascular studies have shown conflicting data regarding plaque burden and morphology between men and women.¹¹⁻²² These invasive studies were though performed in patients with an acute coronary syndrome (ACS), did not evaluate the plaques in the whole coronary tree or did not prospectively investigate sex differences in the natural plaque evolution over a long follow-up period. Coronary computed tomography angiography (CTA) allows for a fast and non-invasive assessment of coronary plaque burden and characterization of plaque composition comparable with intravascular ultrasound virtual histology (IVUS-VH).²³ The aim of the current study was to evaluate the influence of sex on long-term in vivo plaque progression and evolution of plaque composition in a low-to-intermediate risk population in stable clinical conditions. Furthermore, the role of menopause on plaque progression and composition was also evaluated.

MATERIALS AND METHODS


Study design

The SMARTool (Simulation Modeling of coronary ARTery disease: a tool for clinical decision support, Horizon 2020) project, is a prospective, international, multicenter study with the aim of integrating clinical, molecular, cellular and imaging data to provide a patient-specific risk stratification model exploitable for clinical decision support in stable CAD management.^{24,25} Patients who had undergone a coronary CTA at baseline for suspected CAD were prospectively included and subsequently underwent a follow-up coronary CTA. Patients with stable CAD without a history of myocardial infarction, heart failure or surgical procedures related to heart diseases were included. The complete inclusion and exclusion criteria are provided in the supplementary material.

Study population

Patients who had undergone clinically indicated coronary CTA in the period 2009-2012 or were part of the EVINCI (FP7-222915) or the ARTreat (FP7-224297) clinical studies were included. The Diamond-Forrester model was used to estimate the pretest probability of CAD.²⁶ Inclusion and exclusion criteria have been described previously.²⁵ Data on cardiovascular risk factors and medical therapy were prospectively collected at baseline and follow-up. Statin intensity was classified according to the American College of Cardiology and American Heart Association guidelines.²⁷ In total, 275 patients from 5 European countries (Finland, Italy, Poland, Spain and Switzerland) were recruited in 7 centers. Of the 263 patients who underwent a follow-up coronary CTA, 52 patients were excluded because of uninterpretable coronary CTA for visual (n=5) or quantitative CTA analysis (n=11) or absence of coronary plaques at follow-up (n=36). Thus, 211 patients were finally included in the present analysis (Figure 1).

Fig. 1 Flow diagram of the study population



Coronary CTA analysis protocol

The coronary CTA protocol has been described previously.²⁵ In brief, anonymized coronary CTA data were transferred to a core laboratory (Leiden University Medical Center) for visual and quantitative analysis (supplementary material) and researchers were blinded to patients clinical data. Quantitative analysis was performed on visually identified plaques using a dedicated software package (QAngio CT Research Edition version 3.1.2.0, Medis Medical Imaging Systems, Leiden, the Netherlands). The software automatically detects the centerline, lumen and the vessel wall and allows the user for manual adjustment if needed.^{23,28} The baseline and follow-up coronary CTA were analyzed side-by-side and lesions were identified using anatomical markers. Several parameters were derived from the quantitative analysis: percentage diameters stenosis, lesion length, remodeling index, total vessel volume, total plaque volume and plaque composition volumes. Plaque composition volumes were determined using predefined Hounsfield units (HU) cutoff values: >350 HU for calcified plaque and -30 to 350 HU for non-calcified plaque. Non-calcified plaque was further classified in necrotic core plaque (-30 to 75 HU), fibro-fatty plaque (76 to 130 HU) and fibrous plaque (131 to 350 HU). Total plaque volume and plaque composition volumes were normalized for the vessel volume and the percentage atheroma volume (PAV) calculated as follows: (plaque volume/ total vessel volume) x100% and reported as a percentage. The inter- and intra-observer variability have been described previously.²⁸⁻³⁰

Statistical analysis

Continuous variables are expressed as mean \pm standard deviation (SD) if normally distributed and median and interquartile range (IQR) if non-normally distributed. Normality was assessed using histograms and Q-Q plots. Categorical variables are presented as frequencies and percentages and compared using the Chi square test or the Fisher's exact test. Normally distributed continuous variables were compared using the Student's *t*-test and the Mann-Whitney *U*-test if not normally distributed. Quantitative analysis parameters were compared on a per-lesion basis. Analysis of annual rate of lesion progression was performed using linear mixed models (LMM) to correct for per lesion and per patient factors. Fixed effects in the models included sex, interscan period and the interaction between sex and interscan period. In addition, the LMM was adjusted for age, hypertension, diabetes mellitus, smoking, family history of CAD, obesity, LDL and HDL at baseline. Random effects included intercept and an unstructured covariance was used to account for within-

patient and within-plaque correlation over time. A sub-analysis was performed in patients aged under and over 55 years at baseline coronary CTA scan to assess the influence of menopause on plaque progression in women compared to men. The models provide a test for systematic between-group difference across time, as well as a test for between-group differences in the trend. The estimated difference (β) of women compared to men and the interaction are presented with standard error (SE), 95% confidence interval (CI) and p-values. Statistical analyses were performed using SPSS version 25.0 (SPSS, Armonk, NY) and a two-sided p-value <0.05 was considered statistically significant.

RESULTS

Baseline patient characteristics

Of the 211 patients included in the present analysis, 146 (69%) were men and 65 (31%) were women. Women were generally older, had higher HDL levels and presented more often with atypical chest pain. The mean interscan period between baseline and follow-up coronary CTAs was 6.2 ± 1.4 years (minimum 1.9- maximum 11.3). Baseline patient characteristics are shown in Table 1. When stratifying the population according to age groups, 43 (20%) were under 55 years at the time of baseline coronary CTA scan and 168 (80%) were 55 years or older.

Table 1. Patient characteristics

	Total (n=211)	Men (n=146)	Women (n=65)	p-value
Clinical				
Age, years	62 ± 8	61 ± 8	64 ± 7	0.001
Body mass index, kg/m ²	27.6 ± 3.8	27.6 ± 3.4	27.5 ± 4.5	0.835
Family history of CAD	96 (46)	59 (40)	37 (57)	0.049
Current smoker	33 (16)	25 (17)	8 (12)	0.306
Diabetes mellitus	41 (19)	25 (17)	16 (25)	0.266
Dyslipidemia	138 (65)	91 (62)	47 (72)	0.305
Hypertension	136 (65)	90 (62)	46 (71)	0.370
Chest pain	47 (22)	34 (23)	13 (20)	0.310
Typical	96 (46)	56 (38)	40 (62)	0.017
Atypical	1 (1)	1 (1)	0 (0)	1.000
Non-anginal				

Table 1. Continued.

	Total (n=211)	Men (n=146)	Women (n=65)	p-value
Medication				
ACE-inhibitors/ARB's	96 (46)	64 (44)	32 (49)	0.839
Aspirin	133 (63)	90 (62)	43 (66)	0.891
Beta-blockers	86 (41)	55 (38)	31 (48)	0.366
Diuretics	32 (15)	13 (9)	19 (29)	<0.001
Statin therapy				
Statins at baseline	112 (53)	74 (51)	38 (59)	0.296
-High-intensity	7 (6)	4 (5)	3 (8)	0.687
-Low-/Moderate-intensity	34 (30)	25 (34)	9 (24)	0.271
Statins at follow-up	145 (69)	105 (72)	40 (62)	0.133
-High-intensity	27 (19)	19 (19)	8 (20)	0.792
-Low-/Moderate-intensity	110 (76)	78 (77)	32 (80)	0.472
Biochemical				
Creatinine, mg/dl	0.873 ± 0.197	0.943 ± 0.174	0.734 ± 0.166	<0.001
Glucose, mg/dl	109.51 ± 26.63	110.55 ± 26.80	107.42 ± 26.38	0.458
Triglycerides, mg/dL	121.93 ± 62.51	126.92 ± 65.04	111.66 ± 56.13	0.125
Total Cholesterol, mg/dL	185.52 ± 48.32	182.55 ± 48.29	192.23 ± 48.10	0.190
LDL, mg/dL	110.28 ± 41.24	108.35 ± 41.42	114.65 ± 40.84	0.318
HDL, mg/dL	51.33 ± 14.87	49.28 ± 14.53	55.97 ± 14.69	0.003

Bold indicates statistical significance of p-value <0.05.

Patient characteristics are at baseline unless otherwise indicated. Values are presented as mean ± standard deviation or n (%)

ACE = angiotensin-converting enzyme; ARB = angiotensin-II-receptor blocker; CAD = coronary artery disease; HDL = high-density lipoprotein; LDL = low-density lipoprotein

Baseline plaque characteristics and changes of total and compositional PAV

A total of 590 plaques were identified, 434 (74%) plaques were found in men and 156 (26%) in women. Baseline plaque characteristics are shown in Table 2. At baseline men had higher degree of stenosis ($p < 0.05$). Men also had higher absolute volumes of fibro-fatty and necrotic core ($p < 0.05$), but after correction for vessel volume only fibro-fatty PAV remained higher in men ($p < 0.001$). Table 3 summarizes the differences in plaque changes between men and women. Total PAV increased 0.42 %/ per lesion/ per year and 0.34 %/ per lesion/ per year, in men and women respectively, no difference in the progression was observed ($\beta -0.1 \pm 0.1$ (95% CI -0.2 to 0.1) % per year; $p = 0.320$). Similarly, no sex differences in compositional changes

were observed, although women had less fibro-fatty PAV per-lesion compared to men during follow-up (β -1.3 ± 0.4 (95% CI -2.0 to -0.6) %; $p < 0.001$), despite no difference in the rate of plaque progression compared to men ($p = 0.416$) (Figure 2). Examples of quantitative coronary plaque analysis are demonstrated in Figure 3.

Table 2. Plaque characteristics at baseline

Variables	Total (n=590)	Men (n=434)	Women (n=156)	p-value
Lesion length, mm	13.3 (6.5-30.5)	13.4 (6.6-31.6)	13.1 (6.1-24.9)	0.196
Diameter stenosis, %	23.8 (14.5-32.8)	24.6 (14.9-33.5)	21.5 (13.3-30.8)	0.044
Remodeling index	0.85 ± 0.16	0.85 ± 0.16	0.85 ± 0.15	0.973
Total vessel volume, mm ³	247.7 (116.2-528.1)	252.1 (123.5-550.0)	229.6 (101.3-426.4)	0.072
Total plaque volume, mm ³	141.0 (67.5-302.8)	143.3 (70.6-322.3)	133.2 (60.0-239.4)	0.094
Calcified plaque volume, mm ³	7.7 (1.7-23.0)	7.3 (1.7-22.4)	8.5 (1.8-23.3)	0.659
Non-calcified plaque volume, mm ³	123.3 (57.3-269.7)	128.0 (58.7-284.1)	114.7 (52.4-205.7)	0.082
Fibrous plaque volume, mm ³	53.6 (24.7-113.4)	54.3 (24.7-119.1)	50.9 (23.8-105.6)	0.383
Fibro-fatty plaque volume, mm ³	27.8 (12.9-63.1)	29.3 (13.2-68.9)	24.5 (11.0-49.8)	0.009
Necrotic core plaque volume, mm ³	34.4 (15.1-75.4)	37.3 (16.0-82.3)	30.2 (12.5-62.8)	0.032
Total PAV, %	57.9 ± 7.8	57.7 ± 7.7	58.3 ± 7.9	0.453
Calcified PAV, %	3.4 (0.8-7.7)	3.2 (0.8-7.5)	4.1 (1.4-8.3)	0.062
Non-calcified PAV, %	50.6 ± 8.6	50.8 ± 9.0	50.0 ± 7.4	0.304
Fibrous PAV, %	23.0 ± 8.1	22.7 ± 8.1	23.8 ± 8.2	0.167
Fibro-fatty PAV, %	12.0 ± 3.4	12.4 ± 3.5	10.9 ± 2.8	<0.001
Necrotic core PAV, %	15.6 ± 6.6	15.7 ± 6.5	15.3 ± 6.9	0.492

Bold indicates statistical significance of p-value < 0.05

Values are presented as mean \pm standard deviation or median (interquartile range).

PAV = percentage atheroma volume.

Table 3. Plaque morphological and compositional changes on a per-lesion analysis shown for women compared to men


	Total (n=590) $\beta \pm SE$ (95% CI)	p-value
Lesion length, mm		0.116
- Between group comparison	-4.4 \pm 2.8 (-9.9 to 1.1)	0.744
- Interaction	-0.0 \pm 0.0 (-0.0 to 0.0)	
Diameter stenosis, %		0.061
- Between group comparison	-0.0 \pm 0.0 (-0.1 to 0.0)	0.981
- Interaction	0.0 \pm 0.0 (-0.0 to 0.0)	
Remodeling Index		0.758
- Between group comparison	0.0 \pm 0.0 (-0.1 to 0.0)	0.121
- Interaction	-0.0 \pm 0.0 (-0.0 to 0.0)	
Total PAV, %		0.551
- Between group comparison	0.6 \pm 1.0 (-1.4 to 2.6)	0.320
- Interaction	-0.1 \pm 0.1 (-0.2 to 0.1)	
Calcified PAV, %		0.391
- Between group comparison	0.6 \pm 0.7 (-0.8 to 2.1)	0.126
- Interaction	-0.1 \pm 0.1 (-0.3 to 0.0)	
Non-calcified PAV, %		0.500
- Between group comparison	-0.6 \pm 1.0 (-2.5 to 1.2)	0.811
- Interaction	-0.0 \pm 0.1 (-0.2 to 0.2)	
Fibrous PAV, %		0.270
- Between group comparison	1.0 \pm 0.9 (-0.8 to 2.9)	0.559
- Interaction	-0.1 \pm 0.1 (-0.3 to 0.1)	
Fibro-fatty PAV, %		<0.001
- Between group comparison	-1.3 \pm 0.4 (-2.0 to -0.6)	0.416
- Interaction	0.0 \pm 0.0 (-0.1 to 0.1)	
Necrotic core PAV, %		0.704
- Between group comparison	-0.3 \pm 0.7 (-1.7 to 1.1)	0.996
- Interaction	-0.0 \pm 0.1 (-0.2 to 0.2)	

Bold indicates statistical significance of p-value <0.05

Values are presented as estimates (β) \pm standard error (SE) (95% confidence interval)


CI = confidence interval; PAV = percentage atheroma volume

Fig. 2 Plaque changes on a per-lesion analysis shown for women and men



The line graphs represent the estimated average trend from baseline to 12 years for both groups based on a linear mixed modelling, with tests for the systematic between-group differences as well as for differences in trend. Circles represent the estimated mean percentage at the time point the follow-up scan was performed. PAV = percentage atheroma volume

Fig. 3 Quantitative assessment of coronary plaques in a male and female patient at baseline and follow-up.



Panel A represents quantitative coronary plaque analysis of a 62-year-old male patient of the mid-left anterior descending artery at baseline (A1) and after 5.4 years follow-up (A2). During follow-up reduction of necrotic core and an increase in fibrous and fibrous fatty can be observed. Panel B represents quantitative coronary plaque analysis of a 58-year-old female patient of the proximal circumflex artery at baseline (B1) and after 5.9 years follow-up (B2). A reduction of necrotic core and the formation of dense calcium can be observed during follow-up. DS = diameter stenosis

Sex differences and the role of menopause on plaque progression

Table 4 summarizes the differences in plaque progression between men and women stratified according to age (<55 vs ≥55 years). Women had less fibro-fatty PAV in both age groups (<55 vs ≥55 years) compared to men ($p < 0.05$). Women younger than 55 years showed more regression of fibrous PAV ($\beta -0.8 \pm 0.3$ (95% CI -1.3 to -0.3) % per year; $p = 0.002$) and non-calcified PAV ($\beta -0.7 \pm 0.3$ (95% CI -1.4 to -0.1) % per year; $p = 0.027$), compared to men. These differences were absent in the age group ≥ 55 years old (Figure 4).

Table 4. Plaque morphological and compositional changes on a per-lesion analysis shown for women compared to men stratified according to <55 or ≥55 years of age


	<55 years (n=112) β ± SE (95% CI)	p-value	≥ 55 years (n=478) β ± SE (95% CI)	p-value
Lesion length, mm				
Between group comparison	-9.0 ± 9.2 (-27.5 to 9.4)	0.329	-4.2 ± 2.9 (-10.1 to 1.6)	0.151
Interaction	0.0 ± 0.1 (-0.1 to 0.1)	0.871	-0.0 ± 0.0 (-0.1 to 0.0)	0.580
Diameter stenosis, %				
Between group comparison	-0.0 ± 0.0 (-0.1 to 0.1)	0.659	-0.0 ± 0.0 (-0.1 to 0.0)	0.031
Interaction	0.0 ± 0.0 (-0.0 to 0.0)	0.965	0.0 ± 0.0 (-0.0 to 0.0)	0.823
Positive remodeling				
Between group comparison	-0.0 ± 0.1 (-0.1 to 0.1)	0.649	0.0 ± 0.0 (-0.0 to 0.0)	0.563
Interaction	-0.0 ± 0.0 (-0.0 to 0.0)	0.487	-0.0 ± 0.0 (-0.0 to 0.0)	0.125
Total PAV, %				
Between group comparison	1.5 ± 2.9 (-4.3 to 7.3)	0.600	0.1 ± 1.1 (-2.1 to 2.3)	0.919
Interaction	-0.1 ± 0.2 (-0.6 to 0.3)	0.583	-0.1 ± 0.1 (-0.2 to 0.1)	0.329
Calcified PAV, %				
Between group comparison	-0.5 ± 1.4 (-3.3 to 2.4)	0.750	0.3 ± 0.8 (-1.3 to 1.9)	0.733
Interaction	-0.0 ± 0.2 (-0.4 to 0.4)	0.987	-0.1 ± 0.1 (-0.3 to 0.0)	0.130
Non-calcified PAV, %				
Between group comparison	-1.3 ± 2.6 (-6.6 to 4.0)	0.632	-0.5 ± 1.0 (-2.5 to 1.6)	0.652
Interaction	-0.7 ± 0.3 (-1.4 to -0.1)	0.027	0.0 ± 0.1 (-0.2 to 0.2)	0.881
Fibrous PAV, %				
Between group comparison	0.1 ± 2.8 (-5.4 to 5.7)	0.968	0.7 ± 1.0 (-1.2 to 2.7)	0.449
Interaction	-0.8 ± 0.3 (-1.3 to -0.3)	0.002	0.0 ± 0.1 (-0.2 to 0.2)	0.923
Fibro-fatty PAV, %				
Between group comparison	-2.4 ± 1.0 (-4.4 to -0.4)	0.020	-1.0 ± 0.4 (-1.8 to -0.3)	0.010
Interaction	-0.1 ± 0.2 (-0.4 to 0.2)	0.676	0.0 ± 0.0 (-0.1 to 0.1)	0.476
Necrotic core PAV, %				
Between group comparison	0.7 ± 2.0 (-3.3 to 4.8)	0.725	-0.0 ± 0.8 (-1.5 to 1.4)	0.965
Interaction	0.1 ± 0.2 (-0.3 to 0.6)	0.590	-0.0 ± 0.1 (-0.2 to 0.2)	0.744

Bold indicates statistical significance of p-value <0.05

Values are presented as estimates (β) ± standard error (SE) (95% confidence interval)

CI = confidence interval; PAV = percentage atheroma volume

Fig. 4 Plaque changes on a per-lesion analysis shown for women and men stratified according to the age group (<55 vs ≥55 years old)



The line graphs represent the estimated average trend from baseline to 12 years for both groups based on a linear mixed modelling, with tests for the systematic between-group differences as well as for differences in trend. Circles represent the estimated mean percentage at the time point the follow-up scan was performed. PAV = percentage atheroma volume

DISCUSSION

In this prospective and multicenter study of serial coronary CTA we demonstrated that fibro-fatty PAV was higher in men compared to women at any age. During long-term follow-up no sex differences were detected in the change of total or compositional PAV on a per-lesion analysis after correction for multiple cardiovascular risk factors. However, when stratifying patients according to age groups (< 55 vs \geq 55 years), coronary plaques in women younger than 55 years demonstrated more pronounced reduction of fibrous and non-calcified PAV compared to age-matched men. These results provide further insight in the understanding of the role of sex on long-term evolution of plaque morphology in stable CAD.

Similar to previous studies, we found that women had fewer lesions compared to men.^{8,15} However, the total PAV per-lesion at baseline was comparable for men and women, which was also demonstrated in several other studies using IVUS.^{11,14,15,31} In a sub analysis of the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) trial, women had fewer lesions and fewer diseased vessels than men, yet comparable plaque burden on a per-lesion analysis. More importantly, we did not find sex differences in the progression of total PAV during long-term follow-up. Few studies have investigated the influence of sex on quantitatively assessed plaque progression. In a population of 727 men and 251 women, Nicholls et al. also demonstrated no sex differences in the progression of total PAV using IVUS during a follow-up of 18-24 months.¹² Plaque compositional differences between men and women were first reported from limited postmortem studies in patients with advanced CAD and demonstrated coronary plaques in women, especially young women, contained less dense fibrous tissue compared to men.^{7,8} More recently, IVUS-VH studies in patients with ACS demonstrated women tend to have lower fibrous tissue compared to men.^{14,15} This is in agreement with our findings of a greater reduction of fibrous PAV in women younger than 55 years compared to age-matched men. Absolute values of fibro-fatty PAV were higher in men compared to women in both age groups, and at both CTA scan time points, as previously described¹⁵ but its change in time did not differ between men and women. Non-calcified PAV regressed more in women younger than 55 years than in younger men, without any difference in subjects of 55 years or older. Given the known association between non-calcified

plaques with ischemia and ACS, these findings might partially explain the lower risk of symptomatic CAD in young women.³²⁻³⁴

Cardiovascular diseases are increased in women after menopause and the loss of protective female sex hormones has been suggested to play an important role.³⁵ Sex hormones demonstrate a wide range of effects on endothelial cells, vascular tone, lipids, coagulation and cardiomyocytes.³⁵ Consequently, several large randomized trials were conducted to investigate hormone replacement therapy (HRT) following menopause for reducing risk of cardiovascular disease. Although the Women's Health Initiative trials demonstrated no benefit of HRT initiated late after menopause on cardiovascular events,^{36,37} other trials demonstrated that timely starting of HRT was associated with lower progression of atherosclerosis, but did not find evidence for an effect on coronary atherosclerosis progression.³⁸⁻⁴¹ Our findings of a similar progression of total PAV between men and women in both age groups, but differences in compositional changes between men and women younger than 55 years but not in those of 55 years or older is a new insight. Although previous trials have not demonstrate an effect of HRT on total coronary atherosclerosis changes, our findings suggest coronary plaques should be evaluated for compositional changes following HRT. HRT might potentially positively influence plaque compositional changes.

Clinical implications

The higher regression of fibrous and non-calcified PAV in women compared to men younger than 55 years old is a clinically important finding. Non-calcified plaques are associated with ischemia and ACS.²⁸⁻³⁰ The absence of this difference in the, likely post-menopausal, women of 55 years or older hints to a slowing of the regression of non-calcified PAV to match that of the men and thereby increasing the risk for symptomatic CAD. Several strategies could be considered for this increased risk. Monitoring and treatment of cardiovascular risk factors of women around the age of menopause could be employed. Coronary CTA with quantitative plaque assessment might provide additional information on risk for future symptomatic CAD which could prompt early treatment of cardiovascular risk factors. Moreover, HRT might potentially positively influence plaque compositional changes and should be investigated.

Study limitations

Similar to other trials, women were underrepresented in our study. We used 55 years as a proxy for menopause, since menopause status was unavailable from clinical records. Although, the mean age of menopause has been demonstrated to be lower than 55 years, we cannot exclude the fact that premenopausal subjects might have been included in the ≥ 55 years age group.⁴² Furthermore, information on HRT or sex hormone levels, which might have added relevant information, was also unavailable. A relative limited number of patients were included in this study and the sub analysis of sex differences in the different age groups should be interpreted with caution. As coronary CTA scanners from different vendors were used, a predefined standard operating procedure was applied to minimize variances among centers and quantitative analysis was performed in the core lab exclusively on visually recognized plaques: however, although careful visual examination was performed in the whole coronary tree, some plaques might have been unrecognized.

CONCLUSIONS

In a low-to-intermediate risk population of stable CAD with serial CTA scan during a follow-up of 6.2 ± 1.4 years women younger than 55 years demonstrated, after correction for several cardiovascular risk factors, a more pronounced reduction of fibrous and non-calcified PAV compared to age-matched men. No differences in the change of total or compositional PAV were observed between women and men of 55 years or older. Finally, the absolute value of fibro-fatty PAV was consistently higher in men than in women at any age.

REFERENCES

1. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. *Eur Heart J* 2008;29:932-940.
2. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. *J Am Coll Cardiol* 2006;47:S4-S20.
3. Sedlak TL, Lee M, Izadnegahdar M, Merz CN, Gao M, Humphries KH. Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. *Am Heart J* 2013;166:38-44.
4. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. *N Engl J Med* 1999;341:217-225.
5. Lawesson SS, Stenestrand U, Lagerqvist B, Wallentin L, Swahn E. Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction. *Heart* 2010;96:453-459.
6. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. *J Am Coll Cardiol* 2006;47:C13-18.
7. Dollar AL, Kragel AH, Fernicola DJ, Waclawiw MA, Roberts WC. Composition of atherosclerotic plaques in coronary arteries in women less than 40 years of age with fatal coronary artery disease and implications for plaque reversibility. *Am J Cardiol* 1991;67:1223-1227.
8. Mautner SL, Lin F, Mautner GC, Roberts WC. Comparison in women versus men of composition of atherosclerotic plaques in native coronary arteries and in saphenous veins used as aortocoronary conduits. *J Am Coll Cardiol* 1993;21:1312-1318.
9. Farb A, Burke AP, Tang AL, Liang Y, Mannan P, Smialek J, et al. Coronary Plaque Erosion Without Rupture Into a Lipid Core. *Circulation* 1996;93:1354-1363.
10. Burke AP, Farb A, Malcom GT, Liang Y-h, Smialek J, Virmani R. Effect of Risk Factors on the Mechanism of Acute Thrombosis and Sudden Coronary Death in Women. *Circulation* 1998;97:2110-2116.
11. Kornowski R, Lansky AJ, Mintz GS, Kent KM, Pichard AD, Satler LF, et al. Comparison of men versus women in cross-sectional area luminal narrowing, quantity of plaque, presence of calcium in plaque, and lumen location in coronary arteries by intravascular ultrasound in patients with stable angina pectoris. *Am J Cardiol* 1997;79:1601-1605.
12. Nicholls SJ, Wolski K, Sipahi I, Schoenhagen P, Crowe T, Kapadia SR, et al. Rate of progression of coronary atherosclerotic plaque in women. *J Am Coll Cardiol* 2007;49:1546-1551.
13. Qian J, Maehara A, Mintz GS, Margolis MP, Lerman A, Rogers J, et al. Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry). *Am J Cardiol* 2009;103:1210-1214.
14. Hong YJ, Jeong MH, Choi YH, Ma EH, Cho SH, Ko JS, et al. Gender differences in coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. *J Cardiol* 2010;56:211-219.

15. Lansky AJ, Ng VG, Maehara A, Weisz G, Lerman A, Mintz GS, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. *J Am Coll Cardiol Img* 2012;5:S62-72.
16. Stegman B, Shao M, Nicholls SJ, Elshazly M, Cho L, King P, et al. Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. *Atherosclerosis* 2016;254:78-84.
17. Ten Haaf ME, Rijndertse M, Cheng JM, de Boer SP, Garcia-Garcia HM, van Geuns RM, et al. Sex differences in plaque characteristics by intravascular imaging in patients with coronary artery disease. *EuroIntervention* 2017;13:320-328.
18. Chia S, Christopher Raffel O, Takano M, Tearney GJ, Bouma BE, Jang IK. In-vivo comparison of coronary plaque characteristics using optical coherence tomography in women vs. men with acute coronary syndrome. *Coron Artery Dis* 2007;18:423-427.
19. Guagliumi G, Capodanno D, Saia F, Musumeci G, Tarantini G, Garbo R, et al. Mechanisms of atherothrombosis and vascular response to primary percutaneous coronary intervention in women versus men with acute myocardial infarction: results of the OCTAVIA study. *J Am Coll Cardiol Interv* 2014;7:958-968.
20. Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, et al. Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. *Circ Cardiovasc Imaging* 2016;9.
21. Mariani L, Burzotta F, Aurigemma C, Romano A, Niccoli G, Leone AM, et al. Frequency-domain optical coherence tomography plaque morphology in stable coronary artery disease: sex differences. *Coron Artery Dis* 2017;28:472-477.
22. Tian J, Wang X, Tian J, Yu B. Gender differences in plaque characteristics of nonculprit lesions in patients with coronary artery disease. *BMC Cardiovasc Disord* 2019;19:45.
23. de Graaf MA, Broersen A, Kitslaar PH, Roos CJ, Dijkstra J, Lelieveldt BP, et al. Automatic quantification and characterization of coronary atherosclerosis with computed tomography coronary angiography: cross-correlation with intravascular ultrasound virtual histology. *Int J Cardiovasc Imaging* 2013;29:1177-1190.
24. Sakellarios A, Siogkas P, Georga E, Tachos N, Kigka V, Tsompou P, et al. A Clinical Decision Support Platform for the Risk Stratification, Diagnosis, and Prediction of Coronary Artery Disease Evolution. *Conf Proc IEEE Eng Med Biol Soc* 2018;2018:4556-4559.
25. Smit JM, van Rosendael AR, El Mahdiui M, Neglia D, Knuuti J, Saraste A, et al. Impact of Clinical Characteristics and Statins on Coronary Plaque Progression by Serial Computed Tomography Angiography. *Circ Cardiovasc Imaging* 2020;13:e009750.
26. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. *N Engl J Med* 1979;300:1350-1358.
27. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;139:e1046-e1081.
28. Boogers MJ, Broersen A, van Velzen JE, de Graaf FR, El-Naggar HM, Kitslaar PH, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. *Eur Heart J* 2012;33:1007-1016.

29. Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, 3rd, Wenger NK, Bhasin S, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. *JAMA* 2017;317:708-716.
30. de Knecht MC, Haugen M, Linde JJ, Kühl JT, Nordestgaard BG, Køber LV, et al. Reproducibility of quantitative coronary computed tomography angiography in asymptomatic individuals and patients with acute chest pain. *PLoS one* 2018;13:e0207980.
31. Bharadwaj AS, Vengrenyuk Y, Yoshimura T, Baber U, Hasan C, Narula J, et al. Multimodality Intravascular Imaging to Evaluate Sex Differences in Plaque Morphology in Stable CAD. *J Am Coll Cardiol Img* 2016;9:400-407.
32. Versteijlen MO, Kietselaer BL, Dagnelie PC, Joosen IA, Dedic A, Raaijmakers RH, et al. Additive value of semiautomated quantification of coronary artery disease using cardiac computed tomographic angiography to predict future acute coronary syndrome. *J Am Coll Cardiol* 2013;61:2296-2305.
33. Driessen RS, Stuijzand WJ, Raaijmakers PG, Danad I, Min JK, Leipsic JA, et al. Effect of Plaque Burden and Morphology on Myocardial Blood Flow and Fractional Flow Reserve. *J Am Coll Cardiol* 2018;71:499-509.
34. Chang HJ, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, et al. Coronary Atherosclerotic Precursors of Acute Coronary Syndromes. *J Am Coll Cardiol* 2018;71:2511-2522.
35. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. *Science* 2005;308:1583-1587.
36. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-333.
37. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004;291:1701-1712.
38. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. *N Engl J Med* 2016;374:1221-1231.
39. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. *N Engl J Med* 2000;343:522-529.
40. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2001;135:939-953.
41. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. *N Engl J Med* 2003;349:535-545.
42. Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries. *Human reproduction* 2019;34:881-893.

